Immune Reconstitution After Allo-HSCT and Blinatumomab

Not yet recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Leukemia, Lymphoid
Interventions
DRUG

blinatumomab

The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.

All Listed Sponsors
lead

Sichuan University

OTHER

NCT06075212 - Immune Reconstitution After Allo-HSCT and Blinatumomab | Biotech Hunter | Biotech Hunter